{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:43:30Z","timestamp":1793328210428,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81571586"],"award-info":[{"award-number":["81571586"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302559"],"award-info":[{"award-number":["81302559"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Six Talent Peaks Project","award":["2015-WSN-074"],"award-info":[{"award-number":["2015-WSN-074"]}]},{"name":"Jiangsu 333 High Level Talents Project"},{"name":"Jiangsu Government Scholarship for Overseas Studies"},{"name":"iangsu Health International Exchange Program sponsorship"},{"name":"Nanjing Young Medical Talents Project"},{"name":"Nanjing Health Bureau Key Project","award":["ZKX15018"],"award-info":[{"award-number":["ZKX15018"]}],"id":[{"id":"https:\/\/ror.org\/0067hwx77","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Jiangsu Provincial Special Program of Medical Science","award":["BE2015602"],"award-info":[{"award-number":["BE2015602"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1373-2","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T08:00:39Z","timestamp":1500451239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis"],"prefix":"10.1186","volume":"19","author":[{"given":"Huayong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzhu","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"issue":"Suppl 5","key":"1373_CR1","doi-asserted-by":"crossref","first-page":"v44","DOI":"10.1093\/rheumatology\/ken309","volume":"47","author":"L Czirjak","year":"2008","unstructured":"Czirjak L, Foeldvari I, Muller-Ladner U. Skin involvement in systemic sclerosis. Rheumatology (Oxford). 2008;47 Suppl 5:v44\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"1373_CR2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","volume":"70","author":"RT Domsic","year":"2011","unstructured":"Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger Jr TA. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70:104\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1373_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13075-015-0754-7","volume":"17","author":"P Cipriani","year":"2015","unstructured":"Cipriani P, Di Benedetto P, Ruscitti P, Verzella D, Fischietti M, Zazzeroni F, et al. Macitentan inhibits the transforming growth factor-beta profibrotic action, blocking the signaling mediated by the ETR\/TbetaRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2015;17:247.","journal-title":"Arthritis Res Ther"},{"key":"1373_CR4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/ard.2009.111906","volume":"69","author":"FC Arnett","year":"2010","unstructured":"Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK, et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis. 2010;69:822\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1373_CR5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1046\/j.1365-2362.2003.01241.x","volume":"33","author":"EG Czeslick","year":"2003","unstructured":"Czeslick EG, Simm A, Grond S, Silber RE, Sablotzki A. Inhibition of intracellular tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest. 2003;33:1013\u20137.","journal-title":"Eur J Clin Invest"},{"key":"1373_CR6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","volume":"6","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol. 2015;6:272.","journal-title":"Front Immunol"},{"key":"1373_CR7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.071169","volume":"36","author":"SR Johnson","year":"2009","unstructured":"Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol. 2009;36:323\u20139.","journal-title":"J Rheumatol"},{"key":"1373_CR8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","volume":"42","author":"KM Walker","year":"2012","unstructured":"Walker KM, Pope J, participating members of the Scleroderma Clinical Trials C, Canadian Scleroderma Research G. Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2009\u2212\u2009a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42\u201355.","journal-title":"Semin Arthritis Rheum"},{"key":"1373_CR9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/annrheumdis-2013-203674","volume":"73","author":"NP Quillinan","year":"2014","unstructured":"Quillinan NP, McIntosh D, Vernes J, Haq S, Denton CP. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Ann Rheum Dis. 2014;73:56\u201361.","journal-title":"Ann Rheum Dis"},{"key":"1373_CR10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","volume":"44","author":"SL Bosello","year":"2015","unstructured":"Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44:428\u201336.","journal-title":"Semin Arthritis Rheum"},{"key":"1373_CR11","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","volume":"63","author":"D Khanna","year":"2011","unstructured":"Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540\u20136.","journal-title":"Arthritis Rheum"},{"key":"1373_CR12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00296-009-1339-z","volume":"31","author":"E Tinazzi","year":"2011","unstructured":"Tinazzi E, Amelio E, Marangoni E, Guerra C, Puccetti A, Codella OM, et al. Effects of shock wave therapy in the skin of patients with progressive systemic sclerosis: a pilot study. Rheumatol Int. 2011;31:651\u20136.","journal-title":"Rheumatol Int"},{"key":"1373_CR13","first-page":"2213","volume":"144","author":"G Szucs","year":"2003","unstructured":"Szucs G, Szamosi S, Aleksza M, Veres K, Soltesz P. Plasmapheresis therapy in systemic sclerosis. Orv Hetil. 2003;144:2213\u20137.","journal-title":"Orv Hetil"},{"key":"1373_CR14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/clin.1994.1024","volume":"70","author":"PC Dau","year":"1994","unstructured":"Dau PC, Callahan JP. Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol. 1994;70:159\u201365.","journal-title":"Clin Immunol Immunopathol"},{"key":"1373_CR15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","volume":"28","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz Z, Aleksza M, Antal-Szalmas P, Soltesz P, Veres K, Szanto S, et al. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12\u00a0months: follow-up of immunopathological and clinical effects. Clin Rheumatol. 2009;28:347\u201350.","journal-title":"Clin Rheumatol"},{"key":"1373_CR16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1634\/stemcells.2006-0208","volume":"25","author":"PV Guillot","year":"2007","unstructured":"Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells. 2007;25:646\u201354.","journal-title":"Stem Cells"},{"key":"1373_CR17","first-page":"845","volume":"88","author":"PS in \u2019t Anker","year":"2003","unstructured":"in \u2019t Anker PS, Noort WA, Scherjon SA, Kleijburg-van der Keur C, Kruisselbrink AB, van Bezooijen RL, et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica. 2003;88:845\u201352.","journal-title":"Haematologica"},{"key":"1373_CR18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1423-0127-18-49","volume":"18","author":"PM Chen","year":"2011","unstructured":"Chen PM, Yen ML, Liu KJ, Sytwu HK, Yen BL. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci. 2011;18:49.","journal-title":"J Biomed Sci"},{"key":"1373_CR19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2298\/SARH1304178T","volume":"141","author":"D Trivanovic","year":"2013","unstructured":"Trivanovic D, Kocic J, Mojsilovic S, Krstic A, Ilic V, Djordjevic IO, et al. Mesenchymal stem cells isolated from peripheral blood and umbilical cord Wharton\u2019s jelly. Srp Arh Celok Lek. 2013;141:178\u201386.","journal-title":"Srp Arh Celok Lek"},{"key":"1373_CR20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature00870","volume":"418","author":"Y Jiang","year":"2002","unstructured":"Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41\u20139.","journal-title":"Nature"},{"key":"1373_CR21","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1089\/ars.2009.2455","volume":"11","author":"D Paul","year":"2009","unstructured":"Paul D, Samuel SM, Maulik N. Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid Redox Signal. 2009;11:1841\u201355.","journal-title":"Antioxid Redox Signal"},{"key":"1373_CR22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/RLI.0b013e3181ed55f4","volume":"45","author":"S Ju","year":"2010","unstructured":"Ju S, Teng GJ, Lu H, Jin J, Zhang Y, Zhang A, et al. In vivo differentiation of magnetically labeled mesenchymal stem cells into hepatocytes for cell therapy to repair damaged liver. Invest Radiol. 2010;45:625\u201333.","journal-title":"Invest Radiol"},{"key":"1373_CR23","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2007-02-069716","volume":"110","author":"AJ Nauta","year":"2007","unstructured":"Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499\u2013506.","journal-title":"Blood"},{"key":"1373_CR24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1634\/stemcells.2004-0359","volume":"24","author":"PA Sotiropoulou","year":"2006","unstructured":"Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24:74\u201385.","journal-title":"Stem Cells"},{"key":"1373_CR25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.TP.0000045055.63901.A9","volume":"75","author":"WT Tse","year":"2003","unstructured":"Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389\u201397.","journal-title":"Transplantation"},{"key":"1373_CR26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000365483","volume":"22","author":"YY Ooi","year":"2015","unstructured":"Ooi YY, Dheen ST, Tay SS. Paracrine effects of mesenchymal stem cells-conditioned medium on microglial cytokines expression and nitric oxide production. Neuroimmunomodulation. 2015;22:233\u201342.","journal-title":"Neuroimmunomodulation"},{"key":"1373_CR27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri3209","volume":"12","author":"K Blanc Le","year":"2012","unstructured":"Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12:383\u201396.","journal-title":"Nat Rev Immunol"},{"key":"1373_CR28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","volume":"69","author":"J Liang","year":"2010","unstructured":"Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010;69:1423\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1373_CR29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10067-011-1816-0","volume":"31","author":"J Liang","year":"2012","unstructured":"Liang J, Li X, Zhang H, Wang D, Feng X, Wang H, et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol. 2012;31:157\u201361.","journal-title":"Clin Rheumatol"},{"key":"1373_CR30","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2011-11-391144","volume":"120","author":"J Xu","year":"2012","unstructured":"Xu J, Wang D, Liu D, Fan Z, Zhang H, Liu O, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood. 2012;120:3142\u201351.","journal-title":"Blood"},{"key":"1373_CR31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/gutjnl-2011-300083","volume":"61","author":"J Liang","year":"2012","unstructured":"Liang J, Zhang H, Wang D, Feng X, Wang H, Hua B, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut. 2012;61:468\u20139.","journal-title":"Gut"},{"key":"1373_CR32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10456-013-9338-9","volume":"16","author":"P Cipriani","year":"2013","unstructured":"Cipriani P, Marrelli A, Benedetto PD, Liakouli V, Carubbi F, Ruscitti P, et al. Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis. 2013;16:595\u2013607.","journal-title":"Angiogenesis"},{"key":"1373_CR33","doi-asserted-by":"publisher","unstructured":"Vanneaux V, Farge-Bancel D, Lecourt S, Baraut J, Cras A, Jean-Louis F, et al. Expression of transforming growth factor beta receptor II in mesenchymal stem cells from systemic sclerosis patients. BMJ Open. 2013;3(1). doi: 10.1136\/bmjopen-2012-001890 .","DOI":"10.1136\/bmjopen-2012-001890"},{"key":"1373_CR34","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1136\/ard.2011.150607","volume":"70","author":"S Guiducci","year":"2011","unstructured":"Guiducci S, Manetti M, Romano E, Mazzanti B, Ceccarelli C, Dal Pozzo S, et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis. 2011;70:2011\u201321.","journal-title":"Ann Rheum Dis"},{"key":"1373_CR35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/art.39477","volume":"68","author":"AT Maria","year":"2016","unstructured":"Maria AT, Toupet K, Bony C, Pirot N, Vozenin MC, Petit B, et al. Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis. Arthritis Rheumatol. 2016;68:1013\u201325.","journal-title":"Arthritis Rheumatol"},{"key":"1373_CR36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.stem.2012.03.007","volume":"10","author":"K Akiyama","year":"2012","unstructured":"Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-\/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012;10:544\u201355.","journal-title":"Cell Stem Cell"},{"key":"1373_CR37","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","volume":"44","author":"VD Steen","year":"2001","unstructured":"Steen VD, Medsger Jr TA. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 2001;44:2828\u201335.","journal-title":"Arthritis Rheum"},{"key":"1373_CR38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.berh.2009.12.002","volume":"24","author":"D Khanna","year":"2010","unstructured":"Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol. 2010;24:387\u2013400.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1373_CR39","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/rheumatology\/ker447","volume":"51","author":"V Carrai","year":"2012","unstructured":"Carrai V, Miniati I, Guiducci S, Capaccioli G, Alterini R, Saccardi R, et al. Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. Rheumatology (Oxford). 2012;51:1042\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1373_CR40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cei.12111","volume":"173","author":"P Cipriani","year":"2013","unstructured":"Cipriani P, Di Benedetto P, Liakouli V, Del Papa B, Di Padova M, Di Ianni M, et al. Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clin Exp Immunol. 2013;173:195\u2013206.","journal-title":"Clin Exp Immunol"},{"key":"1373_CR41","first-page":"67","volume":"18","author":"CC Doan","year":"2014","unstructured":"Doan CC, Le TL, Hoang NS, Doan NT, Le VD, Do MS. Differentiation of umbilical cord lining membrane-derived mesenchymal stem cells into endothelial-like cells. Iran Biomed J. 2014;18:67\u201375.","journal-title":"Iran Biomed J"},{"key":"1373_CR42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/35043051","volume":"1","author":"J Massague","year":"2000","unstructured":"Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1:169\u201378.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1373_CR43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3727\/096368912X639017","volume":"22","author":"N Scuderi","year":"2013","unstructured":"Scuderi N, Ceccarelli S, Onesti MG, Fioramonti P, Guidi C, Romano F, et al. Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant. 2013;22:779\u201395.","journal-title":"Cell Transplant"},{"key":"1373_CR44","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655\u201366.","journal-title":"N Engl J Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1373-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T19:10:32Z","timestamp":1569870632000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1373-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1373-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]},"article-number":"165"}}